Latham & Watkins Advises on Halozyme Therapeutics’ Convertible Senior Notes Offerings Totaling US$1.3 Billion

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the pricing of US$650 million aggregate principal amount of 0% convertible senior notes due 2031 and US$650 million aggregate principal amount of 0.875% convertible senior notes due 2032. The Company also granted a 13-day option to the initial purchasers to purchase up to an additional US$100 million aggregate principal amount of the 2031 Notes and up to an additional US$100 million aggregate principal amount of the 2032 Notes. The Convertible Notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The Company expects to close the offering on November 12, 2025, subject to the satisfaction of various customary closing conditions.

Latham & Watkins LLP represents the initial purchasers in the offerings with a Capital Markets team led by partners Greg Rodgers and Andrew Blumenthal, with associates Ian Lachow and Steve Hess. Advice was also provided on corporate matters by partners Cheston Larson and Michael Sullivan, with associates Sterling Swift and Samantha Wang; on derivatives matters by partner Reza Mojitabee-Zamani, with associates Sloan Ungerman and Daniel Weiss; on tax matters by partner Bora Bozkurt, with associate Jack Santoro; on FDA regulatory matters by counsel Chad Jennings; on healthcare regulatory matters by partner Betty Pang; and on intellectual property matters by counsel Darryl Steensma, with associate Kristina Funahashi.